Home Newsfeeds Barclays Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $53

Barclays Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $53

Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and lowers the price target from $58 to $53.

byBenzinga Newsdesk

December 12, 2022

1 minute read

Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and lowers the price target from $58 to $53.

Analyst Ratings

Analyst Expectations for Global Payments’s Future

By Benzinga Insights

August 2, 8:00 AM

Global Payments (NYSE:GPN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

GPN

Salesforce Q1 Earnings Preview: Goldman Sachs Expects Beat On These Metrics

By Priya Nigam

May 20, 11:42 AM

Salesforce Inc (NYSE:CRM) has inked a partnership with NTT DATA Group Corp. (OTC:NTDTY) to streamline its application environment.…

CRM

Google Is 6 Months Behind ChatGPT-Parent OpenAI In Artificial Intelligence But ‘About 5 Years Ahead Of Everyone Else,’ Says Gene Munster

By Benzinga Neuro

May 14, 9:20 PM

Munster noted that Google is approximately six months behind OpenAI in terms of AI development, but is still about five years ahead of the rest of the industry. He observed that Google's AI progress is evident in its generative and agentic AI technologies.

GOOG

Specialty Products Maker Brady Increases Annual Dividend By 2%

By Shivani Kumaresan

September 5, 6:47 AM

Brady Corp (NYSE: BRC) said its Board of Directors approved an increase in the annual dividend to shareholders from $0.92 per share to $0.94 per share, representing a 2.2% increase.

BRC

Barclays Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $53

Related Posts

Analyst Expectations for Global Payments’s Future

Salesforce Q1 Earnings Preview: Goldman Sachs Expects Beat On These Metrics

Google Is 6 Months Behind ChatGPT-Parent OpenAI In Artificial Intelligence But ‘About 5 Years Ahead Of Everyone Else,’ Says Gene Munster

Specialty Products Maker Brady Increases Annual Dividend By 2%